• Robust NovoSorb BTM demand across burn and wound indications
• Strong NovoSorb MTX growth with full US launch of 6 mm product
• Completion of BARDA Pivotal Clinical Trial and PMA submission

Polynovo Ltd, a medical device company, has released its FY25 results presentation, showcasing the company's continued progress and global impact. The key highlights include:- Robust demand for NovoSorb BTM across burn and wound indications, driven by increased surgeon adoption- Strong growth in NovoSorb MTX sales, further enhanced by the full launch of the 6 mm product in the US market- Completion of the BARDA Pivotal Clinical Trial and submission of the PMA (Premarket Approval) application to the FDA- Increased focus on reimbursement opportunities and strategies to drive growth- Generation and publication of additional clinical data to support expansion into new indications- Continued geographic expansion with demonstrated clinical and economic distinction within markets- Increased pipeline productivity to drive platform development and value creation- Exploration of external opportunities that bring additional clinical value and financial growth- Significantly increased production capacity enabling compliance and operational efficiencies- Strong cash position and positive cash flow to support future growthThe company's financial performance for FY25 was strong, with total revenue of A$129.2 million, up 23.3% from the previous year. Commercial sales grew by 28.9%, driven by strong growth in the US market (28.7%) and the rest of the world (29.6%). The company also reported positive EBITDA of A$11.2 million, a significant improvement from the previous year.The presentation also highlighted the company's focus on operational excellence, including disciplined execution, expanding and enabling the sales force, and a smooth transition to a new CEO to lead the company through its next stage of evolution.

For FY25, Polynovo Ltd reported:- Total revenue of A$129.2 million, up 23.3% from the previous year- Commercial sales of A$118.6 million, up 28.9% from the previous year- EBITDA of A$11.2 million, a 211.1% increase from the previous year

Polynovo Ltd is focused on driving continued growth and profitability through its robust NovoSorb product portfolio, completion of the BARDA Pivotal Clinical Trial, geographic expansion, and increased pipeline productivity. The company is also exploring external opportunities to bring additional clinical value and financial growth, while maintaining a strong focus on operational excellence and disciplined execution.